
Cyrille Touzeau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7312265/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 374, 1621-1634.	27.0	861
2	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 29-38.	13.7	665
3	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 2017, 130, 2401-2409.	1.4	403
4	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood, 2017, 130, 2392-2400.	1.4	229
5	How I treat extramedullary myeloma. Blood, 2016, 127, 971-976.	1.4	134
6	Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia, 2018, 32, 1899-1907.	7.2	109
7	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 757-767.	1.6	98
8	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1378-1390.	10.7	84
9	Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood, 2016, 128, 2808-2818.	1.4	78
10	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica, 2018, 103, 514-521.	3.5	70
11	Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget, 2015, 6, 8750-8759.	1.8	70
12	Targeting <scp>BCL</scp> â€2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American Journal of Hematology, 2021, 96, 418-427.	4.1	64
13	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood, 2022, 139, 492-501.	1.4	64
14	BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood, 2018, 132, 2656-2669.	1.4	57
15	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 2430-2442.	1.6	53
16	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood, 2015, 125, 3100-3104.	1.4	47
17	Multiple Myeloma: From Front-Line to Relapsed Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e504-e511.	3.8	43
18	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica, 2017, 102, e112-e114.	3.5	43

#	Article	IF	CITATIONS
19	Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open″abel Phase II study. British Journal of Haematology, 2021, 192, 869-878.	2.5	43
20	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia, 2022, 36, 1066-1077.	7.2	39
21	Daratumumab for the treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2017, 17, 887-893.	3.1	35
22	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDC-PET radiomics: a combined analysis of two independent prospective European trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1005-1015.	6.4	35
23	Interest of Pet Imaging in Multiple Myeloma. Frontiers in Medicine, 2019, 6, 69.	2.6	34
24	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). Blood, 2015, 126, 727-727.	1.4	32
25	Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Annals of Hematology, 2019, 98, 1435-1440.	1.8	30
26	Safety and immunogenicity of a first dose of SARS oVâ€2 mRNA vaccine in allogeneic hematopoietic stemâ€cells recipients. EJHaem, 2021, 2, 520-524.	1.0	28
27	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. Blood, 2016, 128, 488-488.	1.4	27
28	<scp>BH</scp> 3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. British Journal of Haematology, 2017, 179, 684-688.	2.5	26
29	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. Blood, 2019, 134, 1875-1875.	1.4	26
30	Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective. OncoTargets and Therapy, 2019, Volume 12, 5813-5822.	2.0	25
31	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research, 2018, 24, 5219-5224.	7.0	24
32	Safety and antibody response after one and/or two doses of BNT162b2 Antiâ€5ARS oVâ€2 mRNA vaccine in patients treated by CAR T cells therapy. British Journal of Haematology, 2022, 196, 360-362.	2.5	24
33	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. International Journal of Molecular Sciences, 2017, 18, 445.	4.1	23
34	Interest of a third dose of BNT162b2 antiâ€SARSâ€CoVâ€2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2022, 196, .	2.5	21
35	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 975-975.	1.4	20
36	T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?. Blood, 2022, 139, 3681-3687.	1.4	20

#	Article	IF	CITATIONS
37	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents Journal of Clinical Oncology, 2022, 40, 8013-8013.	1.6	20
38	Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. Expert Review of Hematology, 2017, 10, 207-215.	2.2	18
39	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Annals of Hematology, 2014, 93, 233-242.	1.8	17
40	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers, 2020, 12, 2532.	3.7	17
41	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget, 2018, 9, 33528-33535.	1.8	17
42	Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies. Cells, 2020, 9, 717.	4.1	16
43	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. Blood, 2015, 126, 3038-3038.	1.4	16
44	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM). Blood, 2016, 128, 674-674.	1.4	16
45	Predictors of survival in patients with surgical spine multiple myeloma metastases. Surgical Oncology, 2016, 25, 178-183.	1.6	13
46	The role of SLAMF7 in multiple myeloma: impact on therapy. Expert Review of Clinical Immunology, 2017, 13, 67-75.	3.0	13
47	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5406.	4.1	13
48	Exposureâ€Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of Clinical Pharmacology, 2021, 61, 614-627.	2.0	12
49	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. Annals of Hematology, 2019, 98, 1441-1447.	1.8	11
50	Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. Leukemia and Lymphoma, 2019, 60, 222-225.	1.3	11
51	Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS). Annals of Hematology, 2021, 100, 1825-1836.	1.8	11
52	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. Blood, 2015, 126, 4219-4219.	1.4	11
53	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 279.e1-279.e4.	1.2	10
54	Newly Diagnosed Myeloma in 2020. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e144-e158.	3.8	9

#	Article	IF	CITATIONS
55	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. British Journal of Haematology, 2022, 197, 82-96.	2.5	9
56	Pomalidomide in the management of relapsed multiple myeloma. Future Oncology, 2016, 12, 1975-1983.	2.4	8
57	ImmunoPET in Multiple Myeloma—What? So What? Now What?. Cancers, 2020, 12, 1467.	3.7	8
58	Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma. Cancers, 2020, 12, 486.	3.7	8
59	Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplantation, 2021, 56, 395-399.	2.4	8
60	Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04 Journal of Clinical Oncology, 2022, 40, 8002-8002.	1.6	8
61	The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. BMC Cancer, 2016, 16, 802.	2.6	7
62	Ixazomib in the management of relapsed multiple myeloma. Future Oncology, 2018, 14, 2013-2020.	2.4	7
63	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. Annals of Hematology, 2020, 99, 1341-1350.	1.8	7
64	No survival improvement in patients with highâ€risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. British Journal of Haematology, 2021, 194, 635-638.	2.5	7
65	Patientâ€reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British Journal of Haematology, 2022, 196, 639-648.	2.5	7
66	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. Cancers, 2020, 12, 1384.	3.7	6
67	Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2020, 136, 10-11.	1.4	6
68	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <scp>JAK</scp> inhibitors era?. European Journal of Haematology, 2017, 99, 60-69.	2.2	5
69	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer, 2019, 19, 855.	2.6	5
70	Monoclonal antibodies as an addition to current myeloma therapy strategies. Expert Review of Anticancer Therapy, 2021, 21, 33-43.	2.4	5
71	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 2254-2260.	2.4	5
72	All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study. Haematologica, 2022, 107, 1693-1697.	3.5	5

#	Article	IF	CITATIONS
73	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the <scp>CANDOR</scp> study. British Journal of Haematology, 2022, 198, 988-993.	2.5	5
74	Global Approaches in Myeloma: Critical Trials That May Change Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 656-661.	3.8	4
75	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta OncolA³gica, 2021, 60, 466-474.	1.8	4
76	High Grade Non-Hodgkin's Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis Blood, 2006, 108, 2045-2045.	1.4	4
77	Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM). Blood, 2021, 138, 83-83.	1.4	4
78	Molecular Signature of ¹⁸ F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine, 2022, 63, 1008-1013.	5.0	4
79	Antiâ€5ARS oVâ€2 vaccines in recipient and/or donor before allotransplant. EJHaem, 2022, , .	1.0	4
80	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine, 2022, 11, 3541.	2.4	4
81	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. Scientific Reports, 2020, 10, 15399.	3.3	3
82	The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. Blood, 2019, 134, 3487-3487.	1.4	3
83	Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd)	1.4	3
84	Cohorts: Blood, 2020, 136, 20 30. Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	3.1	3
85	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. EJHaem, 2020, 1, 318-322.	1.0	2
86	Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. EJHaem, 2022, 3, 533-536.	1.0	2
87	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. Annals of Hematology, 2021, 100, 285-287.	1.8	1
88	Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. Future Oncology, 2021, 17, 993-998.	2.4	1
89	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies Journal of Clinical Oncology, 2021, 39, 8048-8048.	1.6	1
90	Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial. Blood, 2016, 128, 1096-1096.	1.4	1

#	Article	IF	CITATIONS
91	Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon. Blood, 2016, 128, 4428-4428.	1.4	1
92	No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients. Blood, 2015, 126, 2520-2520.	1.4	1
93	Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells. Blood, 2019, 134, 3109-3109.	1.4	1
94	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3911-3911.	1.4	1
95	Efficacy of Imatinib-Based Therapy in a Patient with Resistant NUP214-ABL1 T-Cell Acute Lymphoblastic Leukemia Blood, 2007, 110, 4329-4329.	1.4	О
96	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. Blood, 2015, 126, 3218-3218.	1.4	0
97	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. Blood, 2015, 126, 4339-4339.	1.4	0
98	Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study. Blood, 2015, 126, 1989-1989.	1.4	0
99	Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier. Blood, 2015, 126, 5519-5519.	1.4	0
100	No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2018, 132, 4577-4577.	1.4	0
101	Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study. Blood, 2018, 132, 1484-1484.	1.4	о
102	Influence of Donor Type (sibling vs matched-unrelated donor vs haplo-identical donor vs cord blood) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. Blood, 2018, 132, 3451-3451.	1.4	0
103	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen. Blood, 2019, 134, 1985-1985.	1.4	0
104	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. Blood, 2021, 138, 3465-3465.	1.4	0
105	Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. Blood, 2021, 138, 4914-4914.	1.4	0
106	Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. Blood, 2020, 136, 26-26.	1.4	0
107	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. Blood, 2020, 136, 15-17.	1.4	0
108	Sensitivity to venetoclax: the B-side of myeloma?. Blood, 2021, 137, 3582-3583.	1.4	0

#	Article	IF	CITATIONS
109	Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma. Lancet Haematology,the, 2022, , .	4.6	Ο